Glenmark Pharmaceuticals Limited

NSE: GLENMARK · Healthcare · Lot size: 375

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Glenmark Pharmaceuticals Limited Share Price & Analysis

₹2,210Updated 22 Jul 2026, 03:30 pm IST
LTP
₹2,210
—
Open
₹2,229.8
High
₹2,229.8
Low
₹2,166
Close
₹2,242.1
52W High
₹2,474
52W Low
₹1,793
Volume
942K
Lot Size
375
Sector
Healthcare
Market Cap
₹63K Cr
Face Value
₹1
Large CapNIFTY 200NIFTY 500MIDCAP 100

Price Chart

Fundamentals

P/E
21.4
Sector P/E
54.4
P/B
5.94
EPS
₹37.74
ROE
30.5%
ROCE
39.8%
D/E Ratio
0.06
Div Yield
0.11%
Book Value
₹372
+

Strengths

  • ✓Excellent return on equity (ROE 30.5%)
  • ✓Efficient capital deployment (ROCE 39.8%)
  • ✓Attractively valued vs sector (P/E 21.4x vs industry 54.4x)
  • ✓Virtually debt-free

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
₹7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,939
₹1.3L Cr64.913.5622.117.90.88
CIPLA
Cipla Limited
₹1,416
₹1.1L Cr30.13.3211.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
₹2,405
₹1.1L Cr19.64.928.729.90.32

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

GLENMARK · as of Mar 2026

Promoters46.65%
FII23.15%▼0.36
DII14.60%▲0.75
Public15.56%▼0.40
Govt0.04%
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters46.65%46.65%46.65%46.65%46.65%46.65%
FII23.71%21.38%20.98%23.05%23.51%23.15%
DII10.92%13.36%13.93%13.21%13.85%14.60%
Public18.70%18.58%18.42%17.06%15.96%15.56%
Govt0.04%0.04%0.04%0.04%0.04%0.04%

Corporate Events

To consider and approve the financial results for the period ended Jun 30, 2026

Results30 Jul 2026

To consider and approve the financial results for the period ended March 31, 2026 and dividend

Dividend28 May 2026

Interim Dividend - Rs 2.50 Per Share

Dividend2 Oct 2025

Dividend - Rs 2.50 Per Share

Dividend14 Sept 2025

Dividend - Rs 2.50 Per Share

Dividend12 Sept 2024

Dividend - Rs 2.50 Per Share

Dividend17 Sept 2023

Latest News

All news →

Indian firm wins FDA approval for superbug antibiotic

*Indian firm wins FDA approval for superbug antibiotic* — Glenmark Pharmaceuticals receives US FDA nod for its novel antibiotic, marking a breakthrough in treating drug-resistant infections. The approved drug targets serious bacterial infections with limited treatment options. This paves the way for US market entry and potential revenue growth. Approval underscores India’s rising role in global pharma innovation. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA

thestar.co.za24 Jun
High Impact

Glenmark launches Olanzapine for Injection in USA

*Glenmark launches Olanzapine for Injection in USA* — Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, **10 mg/vial**, a single-dose vial. The product is indicated for schizophrenia and bipolar disorder. This launch expands Glenmark’s presence in the U.S. generics market. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ProductLaunch

NSE Filing6 Jul
Medium Impact

Glenmark advances Phase 3 trial for ovarian cancer drug

*Glenmark advances Phase 3 trial for ovarian cancer drug*. The company has progressed its multi-country Phase 3 clinical trial of Trastuzumab rezetecan in platinum-resistant ovarian cancer. This advancement signals positive momentum in its oncology pipeline. **Phase 3 trials** are pivotal for regulatory approval and market potential. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ClinicalTrial

NSE Filing2 Jul
Medium Impact

Glenmark Pharma launches Methylene Blue injection in USA

Glenmark Pharmaceuticals launched Methylene Blue Injection USP, 50 mg/10 mL in the US market. The product is indicated for the treatment of acquired methemoglobinemia. Launch expands Glenmark’s presence in the US generics segment. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Launch

NSE Filing17 Jun
Medium Impact

Glenmark launches acne drug Winlevi in Europe

*Glenmark launches acne drug Winlevi in Europe* — Glenmark Pharmaceuticals has launched Winlevi® (clascoterone) 10 mg/g cream in key European markets for acne vulgaris. The product launch expands its dermatology portfolio in Europe. Winlevi is a first-in-class topical androgen receptor inhibitor. This move strengthens Glenmark’s presence in the European skincare market. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #DrugLaunch

NSE Filing11 Jun
Medium Impact

Glenmark hosts analyst and investor meet

*Glenmark hosts analyst and investor meet* to discuss business updates and strategy. The company shared insights during its institutional investor presentation. No major financial announcements or guidance changes were disclosed. Event part of routine investor engagement. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

NSE Filing25 Jun
Low Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹3.9K Cr
▼35.5%
₹6.0K Cr
▲85.3%
₹3.3K Cr
▲0.2%
₹3.3K Cr
▼3.9%
₹3.4K Cr
▼1.3%
₹3.4K Cr
▲5.9%
₹3.2K Cr
▲5.9%
₹3.1K Cr
Op. Profit
₹870 Cr
▼63.1%
₹2.4K Cr
▲306.2%
₹581 Cr
▲3.6%
₹561 Cr
▼6.5%
₹600 Cr
▼0.3%
₹602 Cr
▲2.4%
₹588 Cr
▲16.7%
₹504 Cr
OPM
22.0%
▼43.6%
39.0%
▲116.7%
18.0%
▲5.9%
17.0%
▼5.6%
18.0%
▲0.0%
18.0%
▲0.0%
18.0%
▲12.5%
16.0%
Net Profit
₹403 Cr
▼33.9%
₹610 Cr
▲1197.9%
₹47 Cr
▲1075.0%
₹4 Cr
▼98.9%
₹348 Cr
▼1.7%
₹354 Cr
▲4.1%
₹340 Cr
▲128.0%
₹-1.2K Cr
EPS (₹)
14.29
▼33.9%
21.63
▲1203.0%
1.66
▲937.5%
0.16
▼98.7%
12.33
▼1.8%
12.55
▲4.1%
12.06
▲127.9%
-43.17

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Revenue
₹17.0K Cr
▲27.5%
₹13.3K Cr
▲12.8%
₹11.8K Cr
▲2.0%
₹11.6K Cr
▼5.9%
₹12.3K Cr
▲12.4%
₹10.9K Cr
▲2.8%
₹10.6K Cr
▲7.9%
₹9.9K Cr
▲8.7%
₹9.1K Cr
▼0.1%
₹9.1K Cr
Expenses
₹12.4K Cr
▲13.1%
₹11.0K Cr
▲3.3%
₹10.6K Cr
▲6.7%
₹9.9K Cr
▼0.3%
₹10.0K Cr
▲12.6%
₹8.9K Cr
▼0.9%
₹8.9K Cr
▲8.0%
₹8.3K Cr
▲11.0%
₹7.5K Cr
▲5.9%
₹7.0K Cr
Op. Profit
₹4.6K Cr
▲94.5%
₹2.4K Cr
▲96.7%
₹1.2K Cr
▼26.9%
₹1.6K Cr
▼29.7%
₹2.3K Cr
▲11.7%
₹2.1K Cr
▲22.7%
₹1.7K Cr
▲7.1%
₹1.6K Cr
▼1.9%
₹1.6K Cr
▼20.6%
₹2.0K Cr
OPM
27.0%
▲50.0%
18.0%
▲80.0%
10.0%
▼28.6%
14.0%
▼26.3%
19.0%
▲0.0%
19.0%
▲18.8%
16.0%
▲0.0%
16.0%
▼11.1%
18.0%
▼18.2%
22.0%
Other Income
₹-1.8K Cr
▼596.9%
₹-259 Cr
▼177.1%
₹336 Cr
▲3460.0%
₹-10 Cr
▲90.1%
₹-101 Cr
▼206.3%
₹95 Cr
▼50.3%
₹191 Cr
▼49.1%
₹375 Cr
▲321.3%
₹89 Cr
▲302.3%
₹-44 Cr
Interest
₹209 Cr
▲1.0%
₹207 Cr
▼59.9%
₹516 Cr
▲47.9%
₹349 Cr
▲17.1%
₹298 Cr
▼15.6%
₹353 Cr
▼6.4%
₹377 Cr
▲12.5%
₹335 Cr
▲17.1%
₹286 Cr
▲20.7%
₹237 Cr
Depreciation
₹573 Cr
▲17.9%
₹486 Cr
▼16.5%
₹582 Cr
▲2.3%
₹569 Cr
▲16.8%
₹487 Cr
▲9.7%
₹444 Cr
▲6.5%
₹417 Cr
▲27.9%
₹326 Cr
▲7.9%
₹302 Cr
▲14.4%
₹264 Cr
PBT
₹2.0K Cr
▲41.9%
₹1.4K Cr
▲222.4%
₹434 Cr
▼38.6%
₹707 Cr
▼50.9%
₹1.4K Cr
▲4.3%
₹1.4K Cr
▲26.1%
₹1.1K Cr
▼15.8%
₹1.3K Cr
▲16.3%
₹1.1K Cr
▼24.9%
₹1.5K Cr
Tax %
31.0%
▲24.0%
25.0%
▼94.2%
430.0%
▲814.9%
47.0%
▲51.6%
31.0%
▲3.3%
30.0%
▲3.4%
29.0%
▲0.0%
29.0%
▲3.6%
28.0%
▲7.7%
26.0%
Net Profit
₹1.4K Cr
▲30.1%
₹1.0K Cr
▲173.0%
₹-1.4K Cr
▼480.4%
₹377 Cr
▼62.1%
₹994 Cr
▲2.5%
₹970 Cr
▲25.0%
₹776 Cr
▼16.1%
₹925 Cr
▲15.0%
₹804 Cr
▼27.5%
₹1.1K Cr
EPS (₹)
48.26
▲30.0%
37.11
▲169.7%
-53.22
▼605.4%
10.53
▼68.4%
33.37
▼2.9%
34.38
▲25.0%
27.5
▼16.1%
32.78
▲15.1%
28.49
▼27.5%
39.29
Div Payout
5.0%
▼28.6%
7.0%
▲240.0%
-5.0%
▼120.8%
24.0%
▲242.9%
7.0%
▲0.0%
7.0%
▼22.2%
9.0%
▲50.0%
6.0%
▼14.3%
7.0%
▲40.0%
5.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemSep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Liabilities
Equity Capital
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
▲0.0%
₹28 Cr
Reserves
₹9.6K Cr
▲8.3%
₹8.8K Cr
▲12.8%
₹7.8K Cr
▼17.2%
₹9.4K Cr
▲4.3%
₹9.1K Cr
▲28.7%
₹7.0K Cr
▲16.5%
₹6.0K Cr
▲8.3%
₹5.6K Cr
▲8.6%
₹5.1K Cr
▲15.0%
₹4.5K Cr
Borrowings
₹1.2K Cr
▼50.5%
₹2.5K Cr
▲100.9%
₹1.2K Cr
▼73.3%
₹4.6K Cr
▲16.3%
₹4.0K Cr
▼20.5%
₹5.0K Cr
▲2.4%
₹4.9K Cr
▲9.4%
₹4.4K Cr
▼4.1%
₹4.6K Cr
▼1.8%
₹4.7K Cr
Other Liabilities
₹8.2K Cr
▲75.5%
₹4.7K Cr
▼11.6%
₹5.3K Cr
▼0.2%
₹5.3K Cr
▲32.1%
₹4.0K Cr
▲13.6%
₹3.5K Cr
▼5.5%
₹3.7K Cr
▲15.3%
₹3.2K Cr
▲15.8%
₹2.8K Cr
▲9.6%
₹2.5K Cr
Total Liabilities
₹19.0K Cr
▲18.8%
₹16.0K Cr
▲11.4%
₹14.4K Cr
▼25.9%
₹19.4K Cr
▲13.6%
₹17.1K Cr
▲9.5%
₹15.6K Cr
▲6.2%
₹14.7K Cr
▲10.4%
₹13.3K Cr
▲5.5%
₹12.6K Cr
▲7.1%
₹11.8K Cr
Assets
Fixed Assets
₹5.2K Cr
▲16.1%
₹4.5K Cr
▲6.6%
₹4.2K Cr
▼22.4%
₹5.4K Cr
▼7.9%
₹5.9K Cr
▲14.8%
₹5.1K Cr
▲2.0%
₹5.0K Cr
▲37.0%
₹3.7K Cr
▲21.1%
₹3.0K Cr
▲10.0%
₹2.8K Cr
CWIP
₹695 Cr
▼16.8%
₹835 Cr
▲26.1%
₹662 Cr
▼44.4%
₹1.2K Cr
▲17.8%
₹1.0K Cr
▼26.9%
₹1.4K Cr
▲13.1%
₹1.2K Cr
▼12.7%
₹1.4K Cr
▲24.7%
₹1.1K Cr
▲58.5%
₹708 Cr
Investments
₹42 Cr
▼25.0%
₹56 Cr
▼92.9%
₹790 Cr
▲1655.6%
₹45 Cr
▼10.0%
₹50 Cr
▲100.0%
₹25 Cr
▲0.0%
₹25 Cr
▼16.7%
₹30 Cr
▲100.0%
₹15 Cr
▼6.3%
₹16 Cr
Other Assets
₹13.1K Cr
▲23.0%
₹10.6K Cr
▲22.0%
₹8.7K Cr
▼31.6%
₹12.7K Cr
▲25.8%
₹10.1K Cr
▲11.8%
₹9.0K Cr
▲7.7%
₹8.4K Cr
▲2.5%
₹8.2K Cr
▼2.8%
₹8.4K Cr
▲1.7%
₹8.3K Cr
Total Assets
₹19.0K Cr
▲18.8%
₹16.0K Cr
▲11.4%
₹14.4K Cr
▼25.9%
₹19.4K Cr
▲13.6%
₹17.1K Cr
▲9.5%
₹15.6K Cr
▲6.2%
₹14.7K Cr
▲10.4%
₹13.3K Cr
▲5.5%
₹12.6K Cr
▲7.1%
₹11.8K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Operating CF
₹-828 Cr
▼212.5%
₹-265 Cr
▼142.4%
₹625 Cr
▼43.6%
₹1.1K Cr
▼1.9%
₹1.1K Cr
▼18.8%
₹1.4K Cr
▲5.1%
₹1.3K Cr
▼19.7%
₹1.6K Cr
▲150.8%
₹657 Cr
▲90.4%
₹345 Cr
Investing CF
₹58 Cr
▼98.7%
₹4.4K Cr
▲951.8%
₹-515 Cr
▼63.0%
₹-316 Cr
▲52.3%
₹-662 Cr
▲14.5%
₹-774 Cr
▲12.3%
₹-883 Cr
▲12.0%
₹-1.0K Cr
▼0.2%
₹-1.0K Cr
▼5.4%
₹-950 Cr
Financing CF
₹787 Cr
▲120.1%
₹-3.9K Cr
▼4972.7%
₹-77 Cr
▲85.2%
₹-520 Cr
▼17.6%
₹-442 Cr
▲0.7%
₹-445 Cr
▲39.8%
₹-739 Cr
▼57.9%
₹-468 Cr
▼186.2%
₹543 Cr
▼22.3%
₹699 Cr
Net Cash Flow
₹17 Cr
▼92.1%
₹215 Cr
▲571.9%
₹32 Cr
▼88.2%
₹272 Cr
▲871.4%
₹28 Cr
▼83.9%
₹174 Cr
▲158.6%
₹-297 Cr
▼267.8%
₹177 Cr
▼11.1%
₹199 Cr
▲114.0%
₹93 Cr
Free Cash Flow
₹-1.6K Cr
▼35.5%
₹-1.2K Cr
▼1649.3%
₹75 Cr
▼76.6%
₹320 Cr
▼29.8%
₹456 Cr
▼26.0%
₹616 Cr
▼13.5%
₹712 Cr
▲13.9%
₹625 Cr
▲922.4%
₹-76 Cr
▲86.0%
₹-544 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Debtor Days
92d
▲61.4%
57d
▼50.4%
115d
▲25.0%
92d
▲7.0%
86d
▲3.6%
83d
▲2.5%
81d
▼13.8%
94d
▼3.1%
97d
▼19.2%
120d
Inventory Days
254d
▲22.1%
208d
▲2.5%
203d
▼2.4%
208d
▼9.6%
230d
▲9.0%
211d
▼13.5%
244d
▲0.0%
244d
▼18.4%
299d
▲20.1%
249d
Days Payable
216d
▲2.9%
210d
▲22.1%
172d
▼9.5%
190d
▼15.9%
226d
▲7.6%
210d
▼12.9%
241d
▲7.1%
225d
▼7.4%
243d
▼21.1%
308d
Cash Conv. Cycle
129d
▲130.4%
56d
▼61.9%
147d
▲33.6%
110d
▲22.2%
90d
▲7.1%
84d
▼1.2%
85d
▼24.8%
113d
▼25.7%
152d
▲149.2%
61d
Working Capital Days
44d
▲2300.0%
-2d
▼101.4%
141d
▲116.9%
65d
▼3.0%
67d
▲24.1%
54d
▼15.6%
64d
▼35.4%
99d
▼20.8%
125d
▲145.1%
51d
ROCE
19.0%
▲58.3%
12.0%
▲20.0%
10.0%
▼37.5%
16.0%
▲6.7%
15.0%
▲7.1%
14.0%
▼6.7%
15.0%
▲0.0%
15.0%
▼28.6%
21.0%
▲10.5%
19.0%

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Healthcare · Pharmaceuticals & Biotechnology

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
AUROPHARMA
Aurobindo Pharma Limited
Neutral
BIOCON
Biocon Limited
Neutral
CIPLA
Cipla Limited
Neutral

Frequently Asked Questions

What is Glenmark Pharmaceuticals Limited share price today?▾
Glenmark Pharmaceuticals Limited (GLENMARK) is currently trading at ₹2,210 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Glenmark Pharmaceuticals Limited available in F&O (Futures & Options)?▾
Yes, Glenmark Pharmaceuticals Limited (GLENMARK) is part of the NSE F&O segment with a lot size of 375 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Glenmark Pharmaceuticals Limited 52-week high and low?▾
Glenmark Pharmaceuticals Limited's 52-week high is ₹2,474 and the 52-week low is ₹1,793. The current price of ₹2,210 is 10.7% below the 52W high.
What is Glenmark Pharmaceuticals Limited P/E ratio?▾
Glenmark Pharmaceuticals Limited's current P/E ratio is 21.4. This indicates the market is paying ₹21.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Glenmark Pharmaceuticals Limited options?▾
Glenmark Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 375 shares). To trade GLENMARK options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.